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Background: In the study of complex diseases using genome-wide expression data from clinical samples, a difficult
case is the identification and mapping of the gene signatures associated to the stages that occur in the progression
of a disease. The stages usually correspond to different subtypes or classes of the disease, and the difficulty to
identify them often comes from patient heterogeneity and sample variability that can hide the biomedical relevant
changes that characterize each stage, making standard differential analysis inadequate or inefficient.
Results: We propose a methodology to study diseases or disease stages ordered in a sequential manner (e.g. from
early stages with good prognosis to more acute or serious stages associated to poor prognosis). The methodology
is applied to diseases that have been studied obtaining genome-wide expression profiling of cohorts of patients at
different stages. The approach allows searching for consistent expression patterns along the progression of the
disease through two major steps: (i) identifying genes with increasing or decreasing trends in the progression of
the disease; (ii) clustering the increasing/decreasing gene expression patterns using an unsupervised approach to
reveal whether there are consistent patterns and find genes altered at specific disease stages. The first step is
carried out using Gamma rank correlation to identify genes whose expression correlates with a categorical variable
that represents the stages of the disease. The second step is done using a Self Organizing Map (SOM) to
cluster the genes according to their progressive profiles and identify specific patterns. Both steps are done
after normalization of the genomic data to allow the integration of multiple independent datasets. In order
to validate the results and evaluate their consistency and biological relevance, the methodology is applied to
datasets of three different diseases: myelodysplastic syndrome, colorectal cancer and Alzheimer’s disease. A
software script written in R, named genediseasePatterns, is provided to allow the use and application of the
methodology.
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Conclusion: The method presented allows the analysis of the progression of complex and heterogeneous
diseases that can be divided in pathological stages. It identifies gene groups whose expression patterns
change along the advance of the disease, and it can be applied to different types of genomic data studying
cohorts of patients in different states.
Keywords: Disease stage, Disease subtype, Disease progression, Cancer, Leukemia, Transcriptomics, Gene
expression, Gene signature, Expression profiling, Expression pattern, Bioinformatics, Pattern recognition, Data
integrationBackground
Despite the enormous amount of omic datasets produced
from recent biomedical clinical studies of complex dis-
eases –like cancer or neurodegenerative disorders–, the
integration and efficient analysis of these types of large
scale data to achieve a better characterization of the stages
of each disease still remains a challenge. In fact, there are
genome-wide expression studies from clinical samples of
complex pathologies that present subtypes of the disease
in a progressive way, evolving from low-risk and good
prognostic stages to high-risk and poor prognostic stages.
The correct analysis of these stages is very relevant to find
the genes that mark the phases and progression of a dis-
ease and it can not be done by standard differential ex-
pression analyses. The algorithms to analyze time-series
can allow the search for progressive changes in the genes
along several conditions but these methods need the time
as a key parameter to be run [1, 2]. However, many bio-
medical studies have to analyze patients in different clin-
ical stages of the disease without a clear temporal relation.
The patient heterogeneity present in samples from clin-
ical cohorts can hide biomedical relevant changes associ-
ated to the progression and prognosis, making the
standard pairwise comparisons between diseases subtypes
inadequate or inefficient. Moreover, the studies of disease
subtypes often demands increasing the size of the patient
cohorts collecting datasets coming from different hospitals
or research sources that, frequently, have been obtained
with different platforms or in different batches. This ren-
ders the integration problem even harder. To overcome
these limitations, we developed a methodology which al-
lows studying the gene expression transcriptomic profiles
of related disease subtypes using an approach that is ro-
bust to signal variability. Rather than using differential ex-
pression analysis to look for specific markers for each
subtype, our approach is based on a non-parametric co-
expression profiling along the different stages of the dis-
ease followed by the application of a pattern recognition
method. This allows unravelling similarities and identify
specific gene patterns associated to the stages or progres-
sion of the disease. The procedure was initially designed
for the analysis of myelodysplastic syndromes (MDS),which constitute a heterogeneous group of hematological
diseases which often evolve to acute leukemia. However,
the method is generalized to be applicable to the study of
other diseases with stages, and here we illustrate its appli-
cation to two other experimental cohorts of patients from
Alzheimer’s disease (AD) and from colorectal cancer
(CRC), where a clear clinical characterization of the indi-
viduals in stages has been done. All these datasets have
been produced with high-density microarray expression
platforms; therefore, as a validation, we also applied the
methodology to a simulated RNA-seq dataset where a
subset of genes have been modeled to follow progressive
changes in several stages.
Methods
Experimental datasets including categorized samples of
well-defined diseases
The first dataset analyzed in this study corresponds to
bone marrow samples (bone marrow mono-nucleated
cells) from a cohort of myelodysplastic syndrome (MDS)
patients of four subtypes, plus a subset controls that did
not have the disease (i.e. healthy bone marrows) and a
subset of samples from patients with acute myeloid
leukemia (AML, the severe malignant disease where
many high-risk MDSs progress to) (Table 1). The MDS
data were taken from GEO (GSE 13159, https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13159)
[3], that includes a large genome-wide expression study
of patients with different types and subtypes of leukemia
with 2,096 samples (i.e. many different hematological
malignancies) done by an international consortium
(MILE Study). Within this cohort, the subset of MDS
patients was only of 206, and we selected 53 of them for
our study. The World Health Organization (WHO),
based on morphologic evaluation of bone marrow cells
and genetic abnormalities, classifies MDS into 6 major
subtypes: (i) refractory cytopenia with uni-lineage dys-
plasia (RCUD, that usually corresponds mainly to
refractory anaemia); (ii) refractory anaemia with ring
sideroblasts (RARS); (iii) refractory cytopenia with
multi-lineage dysplasia (RCMD); (iv) refractory anaemia
with excess blasts (RAEB-1, <5 % blasts); (v) refractory
Table 1 Number of samples in each dataset of the studied diseases (myelodysplastic syndrome MDS, Alzheimer's disease AD and
colorectal cancer CRC) divided in stages and ordered according to the progression of each disease
Disease subtypes and number of patient samples
Myelodysplastic Synd. (MDS) Control RCUD RCMD RAEB1 RAEB2 AML
Patient samples (N) 11 6 17 4 5 10
Alzheimer’s disease (AD) Control Incipient Moderate Severe
Patient samples (N) 8 7 8 7
Colorectal cancer (CRC) Control Stage 1 Stage 2 Stage 3 Stage 4
Patient samples (N) 25 13 37 34 20
MDS dataset includes 53 samples in 6 stages. AD dataset includes 30 samples and 4 stages. CRC dataset includes 129 samples and 5 stages. The controls
correspond in all cases to samples of individuals without the disease. The stages are placed according to the progression of the diseases from the controls
(no-disease) to the more acute or severe pathological states
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blasts); (vi) MDS associated with isolated del(5q) (that
gives a specific disease: 5q-syndrome) [4]. Blast percent-
age of more than 20 % defines the entrance into AML.
As indicated above, in this study we selected only 53
MDS (coming from 2 Hospitals) because we needed
MDS samples with clear clinical information, including
the level of blast cells (i.e., known % of immature cells in
the bone marrow of the studied patients), as well as
MDS subtypes that can evolve to acute leukemia. For
this reason, we excluded “MDS with ring sideroblasts”
(RARS) that is a low-risk subtype with a very strong iron
signature that usually does not evolve to AML, and “5q-
syndrome” that defines a very specific MDS subtype.
Moreover, only MDS samples with “normal karyotype”
were selected, avoiding cytogenetic abnormalities be-
cause these alterations cause MDS subtypes that usually
have distinct clinical characteristics and treatments. The
platform used to measure expression in all these sample
set was the Affymetrix Human Genome U133 Plus 2.0
Array, that includes readings for 18,950 human genes.
The second dataset corresponds to samples from
hippocampus from a cohort of Alzheimer’s disease (AD)
patients diagnosed at three progressive states of the dis-
ease as classified by the neurologists: incipient, moderate
and severe; plus some control samples of normal hippo-
campus from individuals without the disease (Table 1).
The dataset including 30 samples was taken from
GEO (GSE28146, https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE28146) [5] and the samples were generated
using laser capture micro-dissection to selectively collect
CA1 hippocampal gray matter. In this way, this clinical
cohort –despite the small size– it is very well controlled
and allows focusing the study on the gene expression al-
terations of one specific region of the brain that is most af-
fected in AD [5]. The dataset was generated using the
Affymetrix Human Genome U133 Plus 2.0 Array.
The third dataset corresponds to primary tumor sam-
ples from a cohort of 104 patients with colorectal cancer
(CRC) categorized into four main stages of the tumor,
plus 25 samples from homogenized normal tissue thatwere used as reference control colon samples (Table 1).
Since this dataset included the tumor grade within the
clinical information, we applied the methodology on the
samples classified in 4 main tumor stages, without con-
sidering sub-stages which split the set into smaller
groups but that do not correspond to distinct patho-
logical stages as defined by the oncologists (also because
such sub-stages would contain few samples). All these
samples were taken from GEO (GSE21510, https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21510)
[6] that includes a total set of 129. The disease samples
correspond to cancer cells in 104 patients with CRC iso-
lated using laser micro-dissection to have optimum homo-
geneous cellular material and avoid contamination by
non-tumoral cells. This dataset was also generated using
the Affymetrix Human Genome U133 Plus 2.0 Array.
On the AD and CRC datasets the analyses were done
using directly the processed matrix downloaded from
GEO. These data matrices use the Affymetrix identifiers
(i.e., probesets) for the genes, which were used in the
whole process, and only at the end the probesets were
mapped to genes, ignoring ambiguous probes [7]. The
functional enrichment analyses done on the different gene
lists identified in this work were performed using the bio-
informatic tools Enrichr [8] and GeneTerm Linker [9].
Definition of stages or pathological subtypes along the
progression of each disease
The main requisite underlying the analytic methodology
proposed is that the studied disease –i.e. MDS, AD,
CRC– presents different progressive stages, ranging
from early stages (e.g. lower malignancy or good progno-
sis) to late stages (e.g. advanced stages usually ligated to
bad prognosis). In order to find genes as marking fea-
tures whose expression levels (expression signal) can be
associated to the level of malignancy, the algorithm
searches for genes whose expression evolves following
an increasing or decreasing trend along the disease
stages: being lower at earlier stages and higher at later
stages or vice versa. In this analysis it is important to
keep the context of the disease progression, in addition
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also recommended to have at least one reference stage.
Typically, this will be a control or healthy stage taken as
origin. To provide more statistical power, it is recom-
mended to include a reference of the most malignant
stage, as terminal, even when in some cases it might not
be the focus of the study. The use of these reference
stages, initial and terminal, is specially important when
the intermediate stages may be heterogeneous, fuzzy or
not very well defined from the pathological point of
view. This is, for example, the case for MDSs where sep-
aration between different subtypes of low-risk MDS
stages is frequently not well done or not easy to do, even
for the hematologist doctors, because it can be easily
confused with aplastic anemia [10].
Another point to take into account is the number of
stages included in the study of a disease. More stages will
provide more statistical power to calculate the correlation
and find patterns. However, in some cases it might be in-
teresting to analyze fewer steps in the progression of the
disease in order to concentrate the number of samples
and obtain a more consistent and repetitive result.
Considering all the described conditions the experi-
mental datasets where divided in groups of samples ac-
cording to stages of patients defined by the experts on
each disease. In this way, the MDS (myelodysplastic syn-
drome) dataset analyzed in this study allowed two pos-
sible approaches: (a) applying the methodology
considering 4 MDS disease subtypes (RCUD, RCMD,
RAEB1 and RAEB2); or (b) grouping the subtypes in
two levels by the risk of transforming into acute
leukemia (i.e. RCUD and RCMD into low-risk MDSs,
and RAEB1 and RAEB2 into high-risk MDSs). There-
fore, when including the no-leukemia samples (NoL) as
the initial control stage and AML as the terminal malig-
nant stage, these resulted into two possible scenarios for
analysis: (A) 6 stages contrast: NoL, RCUD, RCMD,
RAEB1, RAEB2, AML; and (B) 4 stages contrast: NoL,
Low-Risk MDS, High-Risk MDS, AML (Fig. 1). In the
case of the AD (Alzheimer’s disease) dataset, 3 progressive
states of the disease were considered: incipient, moderate
and severe; plus the control samples corresponding to the
normal hippocampus from individuals without the disease
(Table 1). In the case of the CRC (colorectal cancer) data-
set, 4 progressive tumor stages were considered: stage 1,
stage 2, stage 3, stage 4; plus the controls corresponding
to the normal colon tissue (Table 1).
Simulated RNA-seq dataset including a subset of genes
altered along several stages
To provide another validation of the method we per-
formed an analysis on simulated data corresponding to a
RNA-seq sample set of a model disease divided in 6
stages, where a small subset of genes have a pattern ofup-regulation or down-regulation along the stages. The
dataset for this simulation was produced with the R
package SimSeq which includes a data-based algorithm
to allow a non-parametric simulation of RNA-seq data
[11]. The experimental dataset used as template to gen-
erate the simulated data was a RNA-seq data matrix in-
cluding 20,531 genes and 72 samples in paired columns
corresponding to individuals with Kidney Renal Clear
Cell Carcinoma (36 replicates in 2 conditions: control
and treated groups). Using this data we random-selected
1000 genes and 18 individuals of the same condition
(control) to generate the simulated distributions. The in-
dividuals were divided in 6 groups of 3 replicates that
correspond to 6 simulated disease stages. Then, 200
random-selected genes where modified in their expres-
sion to have a small change in each stage following 4 dif-
ferent trends: 50 genes up with larger changes at the
initial stages; 50 genes up with larger changes at the late
stages; 50 genes down with larger changes at the initial
stages; 50 genes down with larger changes at the late
stages. All the other 800 genes did not followed any
trend along the stages, despite having different expres-
sion intensities and expression variabilities along the
samples reflecting a typical RNA-seq expression
distribution.
Gamma rank correlation
To search for genes whose expression tends to increase
or decrease as the disease progresses, we calculate the
correlation between the expression of each gene and a
variable that represents the level/stage of the disease (a
categorical/ordinal variable). To do so, we use Goodman
and Kruskal’s Gamma statistic [12], that is a rank-based
correlation measure that calculates the number of inver-
sions in rank ordering for two variables compared. This
coefficient is specially recommended when there are
many ties in any of the variables. In R, we calculate the
Gamma rank correlation through the package RoCoCo
(version 1.1.2) [13], that provides the implementation of
several rank correlation measures taking into account
some peculiarities for noisy data. In this way, Gamma is
calculated as the subtraction of the number of concord-
ant pairs (C, cases with the same order in both variables)
minus the number of discordant pairs (D, cases with dif-
ferent order), divided by the total number of concordant
and discordant pairs:
γ ¼ C  D
CþD
In most implementations, the ranking for the variables
is constructed in a strict manner (i.e. 1.300000001 is
considered bigger than 1.30). Since in case of noisy data,
this can distort the results [14], the authors of the
ab
Fig. 1 Example of disease stages. Scheme showing two ways of setting up the stages of a disease taking MDS case as example. In both cases the
stages must be placed in progressive order considering one initial stage, usually taken as control or normal stage, and one terminal stage that usually
corresponds to the most severe or acute stage of the disease (Acute Disease). The stages are considered as discrete –i.e. not as continuous variables–
and independent –since they correspond to the evolution measured in different individuals–. a An example for 6 stages taken from the MDS case,
considering different disease subtypes. b An example for 4 stages taken from the MDS case, considering only low-risk and high-risk subtypes
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named r, which determines the margin in which both
values will be considered equal, and therefore tied in the
ranking [15]. In all the runs included in this study, we
used for r a 10 % of the interquartile range of the
variables (i.e. the genes). We also set to "linear" the fam-
ily of similarities to compare the order of the variables
(R), and "min" as t-norm (triangular function) to deter-
mine the aggregation of the ordering measures (T). Fi-
nally, to calculate the p-value we used the default value
of 1000 permutations, which was enough to test whether
the association was significant at 95 %, while keeping a
reasonable execution time. The p-values were adjusted
for multiple-testing using False Discovery Rate (FDR)
[16] (implemented in p.adjust function in R) and consider-
ing the total number of genes present in the measuring
platform (i.e. the microarray). The genes with a significant
Gamma (i.e. absolute Gamma > 0.50, and FDR adjusted
p-value < 0.05) were selected as significantly correlated
with the stages and progression of the disease.
Features profiling and patterns recognition
In order to find and identify the possible expression pat-
terns within the genes associated to the pathogenesis of
the disease, a Self Organizing Map (SOM) [17] was ap-
plied. SOM is a robust method for unsupervised cluster-
ing and dimensionality reduction that allows searching
for common profiles produced by variables (i.e. by the
genes) along a series of conditions (i.e. along multiple
samples), grouping such variables according to patterns
of similarity found (Fig. 2a). Only the genes that resulted
in a significant Gamma correlation along the stages of a
disease where introduced in the SOM analysis. To per-
form this clustering analysis and pattern recognition, the
expression of each gene was standardized by subtracting
its mean and dividing by its standard deviation. In this
way, the expression of all the genes was within the same
scale. This normalization step allowed a better integra-
tion of samples from different datasets. For each gene,
the standardized expression values were sorted in as-
cending or descending order (ascending if the mean ex-
pression in the last stage was higher than in the firststage, and descending otherwise). This reordering was
always done following the expression signal intensity
(from high to low, or vice versa) allowing the switch of
position of the samples according to their signal. This
categorization by intensity did not alter the order of
most sample types and it allowed the construction of ro-
bust and consistent profiles because it can compensate
the effect of some noise points. In fact, in the case of the
MDS dataset, we confirmed that most samples in the
last stage (AML) were kept on the final positions, the
control samples (NoL) on the initial positions and the
intermediate-stage samples (MDSs) in the middle
(Fig. 2b: sample color). With this normalized and sorted
expression data, the genes were clustered with the SOM
implementation from Kohonen R package (version
2.0.19) [18]. In all the analyses performed with the three
datasets studied in this work, we used a 3 × 3 grid with
rectangular topology, since this allowed allocating up to
9 possible clusters or groups of genes with similar pro-
files and this was enough in all cases to detect the main
patterns (Fig. 2a).
Results and Discussion
Patterns found along the progression of diseases: three
case studies
In the first dataset studied, corresponding to MDS, we
applied the methodology using 2 different ways of
grouping the samples: by disease subtypes defined in
MDS (6-stage contrast), or by risk of transformation into
leukemia (4-stage contrast) (Fig. 1). The final results ei-
ther way were very similar and coherent with the fact
that the 6-stage contrast is a subdivision of the 4-stage
contrast. Therefore, most of the genes in the 6-stage
contrasts were included in the 4-stage contrasts. This re-
sult shows that the method is able to consider different
number of levels or stages, instead of being forced to
choose a priori just one number of stages.
The application of the method to the MDS dataset, ei-
ther considering 4 or 6 stages, revealed the presence of
four main patterns, that included most of the genes with
a significant correlation (Fig. 2a). Two of the patterns
(patterns MDS 2 and 4) had an expression trajectory
ab
c
Fig. 2 Workflow overview of the results provided by the methodology
proposed. a Expression patterns (clusters) found using SOM on the
correlations obtained for each gene along the stages with the Gamma
rank correlation. Highlighted in blue the 4 patterns selected (for the
case of the MDS dataset) as the most representative of 9 profiles
explored, which included most of the features and the largest
changes: 2 increasing (p1 and p2) and 2 decreasing (p3 and p4). b
Standardized and sorted expression of the genes included in each
pattern. Blue: samples in control or initial stages; red: samples in late or
acute stage; grey: intermediate stages. c Boxplots of the expression
signals of four example genes that follow each one of the 4 patterns
found. These genes also correspond to the MDS dataset and the plots
include 6 stages of the disease
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cant change at the beginning (we named this as early
changing trend); while the other two patterns (patterns
MDS 1 and 3) had a drastic change just at the end, fol-
lowing a linear-to-exponential-like trajectory (we named
this as late changing trend) (Fig. 2b). The δ/2 threshold
within each pattern (i.e. the point that locates the 50 %
change in the total range of expression change), allowed
to confirm the trends described, because while for pat-
terns MDS 2 and 4 the δ/2 point lies approximately at
the initial stages (i.e. at MDSs of low-risk), for patterns
MDS 1 and 3, it lies at the end, closer to the acute stage
that is AML (Fig. 2b). It is known that myelodysplastic
syndromes include a quite heterogeneous set of
hematological malignancies. Even within the subgroups
currently defined by medical consortiums, there is still
considerable clinical heterogeneity [19]. This heterogen-
eity is also reflected at genetic level, where there are sev-
eral molecular features known to be associated with
MDS (e.g. specific chromosomal alterations or mutations
in some specific genes like RUNX1, TP53 or SF3B1), but
each of them is not necessarily present in every patient
[20, 21]. In this way, the methodology presented pro-
vides a powerful alternative to the traditional differential
expression analyses, since many of the gene changes that
were detected here (Fig. 3a) would be lost with such
analyses due to the small significance of the expression
changes in pair-wise comparisons between two subtypes
and also due to the frequent sample heterogeneity. Com-
ments about the specific genes found and their functions
are included below in the last paragraphs of the Results
and Discussion section.
The analyses done on the other two datasets of AD
and CRC also allowed the discovery of interesting pat-
terns in the progression of these diseases. Figure 3b pre-
sents the four main patterns found for Alzheimer (AD)
and it can be seen that these trends are steeper than the
ones observed for MDS and so they indicate a sharp
progression along the analyzed stages. Two of the pat-
terns (patterns AD 1 and 2) correspond to groups of
genes with an expression trajectory that increases
ab
c
Fig. 3 Patterns found in the analyses of the gene-stage expression
profiles of 3 disease datasets. a Myelodysplastic Syndrome, MDS. b
Alzheimer’s Disease, AD. c Colorectal Cancer, CRC. The results correspond
to the outputs of the SOM analyses done in all cases with a maximum of
9 (3x3) possible distinct profiles. In all cases 4 significant patterns were
found. The number of genes included in each pattern are indicated in
each case
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other patterns (patterns AD 3 and 4) correspond to
groups of genes with trajectory that is high in the con-
trol initial samples but decreases sharp towards the final
stages of AD. The number of genes grouped in these
trends is not very big due to the fact the AD dataset is
the one with fewer samples and fewer stages (Table 1).
Despite this limitation, the genes found –as discussed
below– are quite relevant and show the value of the
methodology.
Finally, Fig. 3c presents the four main patterns found
for colorectal cancer (CRC) along its progression from
early tumor stages to advanced stages. In this case three
of the main patterns (patterns CRC 1, 2 and 3) corres-
pond to groups of genes with expression trajectory thatdecreases towards the final stages of CRC; and only one
(i.e. pattern CRC 4) includes genes that have low expres-
sion in the control samples that increases in the CRC
stages. The patterns found for this dataset also include
quite interesting genes associated to CRC, that are dis-
cussed below in the last part of this section.
Patterns found in the simulated RNA-seq dataset
As indicated in the Methods section, we generated a
simulated RNA-seq dataset with 1000 genes that models
a disease including 18 samples on 6 stages, with a subset
of 200 genes that followed 4 patterns of up-regulation or
down-regulation along the stages. The application of our
methodology on this dataset showed the performance of
the method in finding the genes that belong to each pat-
tern. The results are presented in Fig. 4, showing that
201 genes were assigned to 4 patterns, resulting in a very
good performance with only 1 false positive included in
pattern 2 (i.e., in this pattern the method detected 51
genes instead of 50 genes expected). This analysis indi-
cates a 99 % accuracy and, despite being on simulated
data, it shows that the methodology can be applied to
different types of data and it is able of finding a signal
inside a nonparametric data matrix where 80 % of the
genes were not positive. The gene that is “false” had a
very low expression level (lower than 1 in most of the
samples, see Fig. 4a) and this reveals a common problem
in expression profiling where most mistakes are pro-
voked by the low-expression genes, since very small
changes on then can mark significant differences.
Genes associated to the disease progression: functional
and biological findings
All the specific genes found on the experimental datasets
as associated to the patterns of each disease are included
in three Additional files. The genes found for MDS in
Additional file 1: Table S1; the genes found for AD in
Additional file 2: Table S2; the genes found for CRC in
Additional file 3: Table S3. We have also done functional
enrichment analyses with the lists of genes associated to
some of the patterns found in each one of these diseases,
in order to see the biological coherence of the results.
These functional enrichment results are included in
Additional file 4: Table S4, that presents the enrichment
on biological terms associated to the genes included in
the following patterns: the expression pattern 1 of MDS
(24 genes UP-regulated) (Fig. 3a); the expression pattern
4 of AD (39 genes DOWN-regulated) (Fig. 3b); and the
expression patterns 2, 3 and 4 of CRC (168 genes that
are all the genes DOWN-regulated in this disease)
(Fig. 3c).
The interest of the genes included in the patterns
found for each disease is supported by the finding of
some genes that are well-known markers of the
ab
Fig. 4 Patterns found in the analyses of the expression patterns of a simultaed RNA-seq dataset. The dataset includes RPKM signals for 1000 genes and 18
samples divided in 6 stages. a Outputs of the SOM analysis that identifies 4 main patterns including: 50 genes up-early, 51 up-late, 50 down-early and 50
down-late. In this 201 genes found, only one was a false positive and there are not any false negatives. b Plots of expression distributions of the genes
found in each pattern. The plots represent the expression signal distributions (as log2 of the RPKM values +1) of the genes in each of the 4 patterns
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ology. This is the case, for example, of the 24 genes
included in MDS pattern 1 that are the most clearly UP-
regulated genes in the late stages of this disease and, in
this way, should mark the entrance in acute leukemia
(AML). The enriched functions found show that these
genes are related with hematopoiesis (GO:0030097) and
mark a negative regulation of myeloid cell differentiation
(GO:0045638) indicating a tendency to generate undif-
ferentiated cells (Additional file 4: Table S4A). In fact,
many of these genes have been reported as related to
AML: ANGPT1, FLT3, HOXA3, HOXA7, HOXA9,
HOXB2, HOXB3, MEIS1. For example, FLT3 and
MEIS1, are clear AML markers and the appearance up-
regulated at the late stages of MDS supports an evolu-
tion towards such acute leukemia states [21]. The same
occurs with the cluster of HOX genes (HOXA3,
HOXA7, HOXA9, HOXB2 and HOXB3) that are well
reported as genes that are up-regulated in AML. These
results show that the methodology allows finding genes
relevant to the analyzed disease.
With respect to new genes found in other MDS pat-
terns, the one assigned to pattern MDS 3 with the most
significant Gamma correlation was LCN2. Higher LCN2
(lipocalin 2) expression in bone marrow of patients has
been recently identified as an independent favorable prog-
nostic factor in acute myeloid leukemia [22]. Therefore, its
repression in the progression of MDSs, as we observed
when this gene is included in MDS pattern 3, can indicate
the propensity towards more malignant states.With respect to genes marking the early stages of MDS
progression, we found that the gene most significantly as-
sociated to MDS pattern 4 (showing a Gamma correlation
of 0.739) was UCA1 (urothelial cancer associated 1), that
is a long non-coding RNA (lncRNA). This gene has gained
great attention in recent years due to its aberrant expres-
sion in a broad range of cancer tissues and cells [23]. We
also detected in this pattern ORM1 and ORM2. Human
orosomucoid (ORM) is a major acute-phase plasma pro-
tein (encoded by 2 highly homologous genes) that is in-
duced as a reaction to inflammation, infection, injury or
cancer. In this way it is quite remarkable the observation
of the induction of these genes in the MDS pattern 4, that
represents an early stage of the disease revealing genes
that are up-regulated in the initial low-risk MDS subtypes
(as shown with the early changing trend in Fig. 2b).
With regard to AD, despite the fact that the number
of samples analyzed for this dataset was smaller than in
the other two cases, we found some interesting genes
associated to the disease progression patterns. The en-
richment analysis done on the genes of AD pattern 4,
that is the pattern including most genes (Additional file 4:
Table S4B), shows a down-regulation of neuro-transmission
and synapsis functions (GO:0007269, GO:0001505,
GO:0035249) determined by genes: GLS, GRIA3, LIN7A
and SLC17A7. This functional mark would be expected in
AD patients in the progression of their disease. By con-
trast, in the case of AD pattern 1, 9 genes of up-regulation
were found and several of these genes have been previ-
ously reported as altered in AD, including the top gene of
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DEFB125: which is a defensin with expression up-
regulated in Alzheimer’s brain [24]. Moreover, gene
KIF1B, that was the most significant in AD pattern 2,
has been implicated in different forms of human neuro-
degenerative diseases, playing a role in the function and
regulation of synaptic signaling [25]. It is also interest-
ing the identification of gene ARHGAP20 as the most
significant included in AD pattern 4, because very re-
cently this gene has been found in the first genome-
wide association study (GWAS) of cognitive decline in
AD with longitudinal measures of cognition published
Sherva et al. [26]. The association of this gene to Alzhei-
mer’s disease severity and progression is a new observa-
tion derived from the methodology here proposed, and
it is supported by the reported study about the rate of
cognitive decline in AD.
Finally, in the case of CRC the enrichment analysis
done on the 168 genes that show patterns of down-
regulation on this disease (CRC patterns 2, 3 and 4)
(Additional file 4: Table S4C), shows multiple functions
related to a repression of cellular responses
(GO:0071868, GO:0071870, GO:0009611) and negative
regulation of cytokine-mediated signaling (GO:0001960)
determined by genes: ADIPOQ, CACTIN, GNG2,
PDE4D, SLIT3, SNCA. A lack of response to damage on
the cells seems to be a signature that these expression
patterns reveal for colon cancer progression. Some of
the repressed genes (i.e. BCL2, TNFRSF10C and
TNFRSF1A) also indicate a negative regulation of apop-
tosis, that is very much associated with tumor progres-
sion. It is also quite interesting to find that one of the
most clearly inhibited genes following CRC pattern 2, is
SDPR, a cavin family protein (serum deprivation re-
sponse factor-related gene product) that binds to C-
kinase (PKC) and has been found as epigenetically inac-
tivated in gastric cancer and in breast cancer [27]. Re-
moval of this protein causes caveolae loss, i.e. plasma
membrane lipid rafts loss, and this membrane vesicle
trafficking is an essential function of the normal colon
epithelium. Another interesting gene discovered in the
repression patterns of CRC (pattern 4) is MTUS1, since
it has been recently reported that loss of MTUS1 in gas-
tric cancer promotes tumor growth and metastasis [28].
With respect to CRC pattern 1, that is the only one
showing up-regulation, we found reports of some novel
genes included in this pattern that can be related to the
progression of the disease, like for example squalene
epoxidase (SQLE) that is up-regulated in breast cancer
and indicates poor clinical outcome in early stages of
this disease [29]. Another very interesting protein found
in this CRC pattern is KLHL20, a BTB-kelch protein
that is involved colon cancer metastasis since it is a sub-
strate adaptor of CUL3 E3 ligase complex catalyzing theubiquitination of DAPK (death-associated protein kin-
ase) a well-known tumor suppressor [30].
The functional demonstration of the role of each gene
included in the patterns found for MDS, AD and CRC
on the progression of these diseases is out of the scope
of this work; but the results presented in this manuscript
provide enough data to shown the biological coherence
and consistency of the gene-disease-patterns found and
to validate the methodology proposed. In this way, the
scope of this work is to present a useful analytical meth-
odology applied to several independent datasets and to
provide tools and means to allow that other researchers
can use it (supplying an R software to do it). To this
scope, we show in this work that several of the genes
found for the studied diseases have expected meaning
and coherence, and are consisting with multiple pub-
lished reports. In fact, a deeper biological analysis of
MDS (exploring its evolution along stages and the gene
patterns that are behind the progression of this disease)
will be included in another publication that we are pre-
paring in collaboration with clinical doctors, where we
will focused on the biological interpretation of the find-
ings and their relevance to the understanding of the
MDS disease. In such complementary work, we have
combined more series of MDS produced with different
expression platforms (i.e., Affymetrix HGU133 plus 2.0
arrays and Affymetrix Human Exon arrays). We have
also compared the results of these datasets with other
independent studies on MDS, like one from pediatric
MDS (done on bone marrow mononuclear cells) and an-
other from MDS patients (done on CD34+ cells). All
these analyses are not included in the present manu-
script, but they allow us to indicate that we have applied
the proposed methodology to other datasets of the same
disease and we have found similar results.
Conclusions
The method here presented allows the analysis of the
evolution of complex and heterogeneous diseases includ-
ing different pathological subtypes in stages. The pro-
cedure identifies gene groups moving in a coordinated
way along a series of associated stages. In particular, the
methodology analyses genome-wide expression profiles
to find patterns of genes associated to the changes along
the progression of the disease stages, showing a new way
to achieve a robust profiling of transcriptomic data from
different sets of patients that are measured at discrete
states along the phases of the disease.
Depending on the scope of each specific study, the
focus of the analyses can be on the alterations that hap-
pen at initial stages, at the final transformation or even
at intermediate stages in a fuzzy way. In order to provide
a clearer overview of the studied stages, it is recom-
mended to have at least four or five stages, including
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stage” corresponding to the most acute state of the dis-
ease. As a minimal number of samples required at each
stage, we recommend that any study should include at
least three biological replicates per stage.
Finally, in this work the methodology has been success-
fully applied to three independent experimental datasets
that study complex diseases. We also applied it to a simu-
lated RNA-seq dataset. The results show that the proced-
ure can be very useful to analyze heterogeneous diseases
without the need of having clear subdivisions (i.e., enclos-
ing subtypes that still have to be defined), as long as the
samples are placed in stages along the progression of the
disease. The results also show that the method is applic-
able to different types of expression and transcriptomic
data, including RNA-seq data.Additional files
Additional file 1: Table S1. Significant genes found in the patterns
associated to the progression of MDS: A total set of 189 genes were
found. These genes are included in one of the 4 patterns identified
(marked in red colors in the case of the 2 increasing trends or green
colors in the case of the 2 decreasing trends). The Gamma correlation
factor and the adjusted p-value of such correlation are included for each
gene in its pattern. (XLSX 79 kb)
Additional file 2: Table S2. Significant genes found in the patterns
associated to the progression of AD: In total 74 genes were found as
significant assigned to one of the 4 AD patterns. The patterns are marked in
red colors in the case of increasing trends or green colors in the case of
decreasing trends. The Gamma correlation factor and the adjusted p-value
of such correlation are included for each gene in its pattern. (XLSX 13 kb)
Additional file 3: Table S3. Significant genes found in the patterns
associated to the progression of CRC: A total set of 243 genes were
included in 4 patterns: 1 increasing and 3 decreasing. Each one of the
four patterns is marked in a color (red colors in the case of increasing
trends or green colors in the case of decreasing trends). The Gamma
correlation factor and the adjusted p-value of such correlation are
included for each gene in its pattern. (XLSX 25 kb)
Additional file 4: Table S4. Functional Enrichment Analyses of lists of
genes included in the expression patterns found along the progressive
stages of 3 diseases: MDS, AD, CRC. (A) Functional enrichment on terms
from Gene Ontology Biological Process (GO-BP) for the 24 genes included
in MDS pattern 1. (B) Functional enrichment on GO-BP terms for the 39
genes included in AD pattern 4; (C) Functional enrichment on GO-BP terms
for the 168 genes included in CRC patterns 2, 3 and 4. (XLSX 15 kb)
Additional file 5: Software script named genediseasePatterns, that
allows the use of the method presented in this work using R (software
environment for statistical computing: https://www.r-project.org/). This
software is provided as a .zip folder (named "genediseasePatterns_
R_script.zip") including the following files. genediseasePatterns_
workflow.html; gene-diseasePatterns_workflow.Rmd; resultGAMMA.RData;
resultSOM.RData; GSE28146_series_matrix.txt. The .zip folder is available
at: http://bioinfow.dep.usal.es/genediseasePatterns/.Abbreviations
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